Jefferies Assumes Progenics Pharmaceuticals (PGNX) at Buy
Tweet Send to a Friend
Jefferies assumes coverage on Progenics Pharmaceuticals (NASDAQ: PGNX) with a Buy rating and a price target of $9.00 (from $8.00).Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE